Smith & Nephew (SN) Receives a Buy from Goldman Sachs
Goldman Sachs analyst Richard Felton reiterated a Buy rating on Smith & Nephew yesterday and set a price target of p1,700.00. The company’s shares closed yesterday at p1,336.00.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
According to TipRanks, Felton is a 3-star analyst with an average return of 4.7% and a 55.46% success rate. Felton covers the Healthcare sector, focusing on stocks such as Fresenius Medical Care AG & Co. KGaA, Fresenius SE & Co. KGaA, and GN Store Nord.
In addition to Goldman Sachs, Smith & Nephew also received a Buy from Bank of America Securities’s Julien Ouaddour in a report issued yesterday. However, on the same day, TipRanks – xAI reiterated a Hold rating on Smith & Nephew (LSE: SN).
Based on Smith & Nephew’s latest earnings release for the quarter ending December 31, the company reported a quarterly revenue of p3.31 billion and a net profit of p342.47 million. In comparison, last year the company earned a revenue of p2.98 billion and had a net profit of p198 million
Read More on GB:SN:
Disclaimer & DisclosureReport an Issue
- Smith & Nephew: Building Momentum Toward FY26 Targets With New Products and Orthopaedics Driving Upside
- Smith & Nephew price target raised to 1,305 GBp from 1,290 GBp at Barclays
- Smith & Nephew: Resilient Fundamentals and Earnings Momentum Support Buy Rating
- Smith & Nephew announces U.S. distribution agreement with RMR Ortho
- Smith & Nephew signs distribution agreement with SI-Bone
